Article
Oncology
Yi-Hsin Liang, Kuo-Hsing Chen, Yu-Yun Shao
Summary: Adding anti-EGFR mAb to first-line chemotherapy for KRAS wild-type mCRC is associated with significantly longer overall survival and time to treatment failure, especially in left-sided primary tumors.
Article
Oncology
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang
Summary: The purpose of this study is to determine the impact of KRAS gene mutations on the efficacy of panitumumab monotherapy for metastatic colorectal cancer (mCRC). Through testing on 463 patients, it was found that 43% of patients had KRAS mutations. The results showed that panitumumab significantly improved overall survival and progression-free survival for patients with wild-type KRAS, while no significant efficacy was observed for patients with KRAS mutations. Therefore, KRAS status should be taken into account when selecting mCRC patients for panitumumab monotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Marwan G. Fakih, Lisa Salvatore, Taito Esaki, Dominik P. Modest, David P. Lopez-Bravo, Julien Taieb, Michalis V. Karamouzis, Erika Ruiz-Garcia, Tae-Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun-Huei Yeh, Emily Chan, Joseph Chao, Yaneth Saportas, Qui Tran, Chiara Cremolini, Filippo Pietrantonio
Summary: In this study, the combination of KRAS G12C inhibitor sotorasib and EGFR inhibitor panitumumab showed longer progression-free survival compared to standard treatment in patients with chemorefractory metastatic colorectal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Immunology
Tong Liu, Shuai Jiang, Xue Teng, Lu Zhong, Mengmeng Liu, Yao Jin, Mei Dong
Summary: In the treatment of metastatic colorectal cancer, there was no significant difference in overall survival, progression free survival, and response rate between cetuximab and panitumumab. However, there were differences in adverse reactions, with decreased incidence of paronychia in the panitumumab arm and decreased incidence of hypomagnesemia in the cetuximab arm.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
(2023)
Article
Oncology
Jonathan M. Loree, Yucai Wang, Muddassir A. Syed, Alexey Sorokin, Oluwadara Coker, Joanne Xiu, Benjamin A. Weinberg, Ari M. Vanderwalde, Anteneh Tesfaye, Victoria M. Raymond, Benjamin Miron, Gabi Tarcic, Ori Zelichov, Russell R. Broaddus, Patrick Kwok Shing Ng, Kang Jin Jeong, Yiu Huen Tsang, Gordon B. Mills, Michael J. Overman, Axel Grothey, John L. Marshall, Scott Kopetz
Summary: The study identified a high prevalence of atypical RAS mutations in colorectal cancer patients, which were associated with poor prognosis. Activating atypical variants were the most common in clinical cohorts, providing the best evidence to guide treatment.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo De Braud, Ravit Geva, Mark T. J. van Bussel, Katia Fiorella Dotti, Elena Elez, Maria J. de Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris
Summary: This study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF (V600E)-mutant metastatic colorectal cancer. The results showed a high incidence of adverse events and no evidence of improved anti-tumor activity, leading to study discontinuation.
Article
Oncology
Danyang Li, Feng Wang, Shuning Xu, Ke Li, Xiangrui Meng, Yangyang Huang, Ning Ma, Lei Qiao, Gaizhen Kuang, Jinghong Chen, Ying Liu
Summary: In this study, no significant difference was found in progression free survival (PFS), overall survival (OS) and objective response rate (ORR) between continuing cetuximab and bevacizumab plus chemotherapy crossover after the first progression to cetuximab regimen in wild-type KRAS, NRAS and BRAF V600E metastatic colorectal cancer. However, there was a trend favoring the continuation of cetuximab in all end points. High expression of MET in cetuximab-progressed tumors may indicate an existence of MET-dependent tumor cell population.
Article
Oncology
Chengren Zhang, Lili Liu, Yaochun Lv, Jingjing Li, Cong Cao, Jiyong Lu, Shuai Wang, Binbin Du, Xiongfei Yang
Summary: The meta-analysis showed that for wild-type KRAS/RAS metastatic colorectal cancer patients, EGFR inhibitors were superior to VEGF inhibitors in prolonging overall survival and overall response rate, with no significant difference in progression-free survival. The survival benefit of EGFR inhibitors was mainly observed in first-line treatment.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Article
Oncology
Jonathan D. Sorah, Dominic T. Moore, Matthew J. Reilley, Mohamed E. Salem, Tammy Triglianos, Hanna K. Sanoff, Autumn J. McRee, Michael S. Lee
Summary: This study investigated the treatment strategy of anti-EGFR rechallenge for patients with KRAS wild-type metastatic colorectal cancer (mCRC). However, the results showed that selecting patients based on clinical criteria alone and using palbociclib+cetuximab was not effective enough. Additional biomarkers are needed to assist in selecting the treatment strategy.
Article
Oncology
Aparna R. Parikh, Elena Gonzalez-Gugel, Natalia Smolyakova, Min-Hua Jen, Nikki Toms, Yong Lin, Jong Seok Kim, Scott Kopetz
Summary: This meta-analysis compares the efficacy and safety of Q2W and Q1W cetuximab administration in patients with colorectal cancer. The results show that there is no significant difference in efficacy and safety between the two treatment regimens.
Article
Oncology
John H. Strickler, Christel N. Rushing, Hope E. Uronis, Michael A. Morse, Donna Niedzwiecki, Gerard C. Blobe, Ashley N. Moyer, Emily Bolch, Renee Webb, Sherri Haley, Ace J. Hatch, Ivy P. Altomare, Gary B. Sherrill, David Z. Chang, James L. Wells, S. David Hsu, Jingquan Jia, S. Yousuf Zafar, Andrew B. Nixon, Herbert I. Hurwitz
Summary: The combination of cabozantinib and panitumumab has shown activity in patients with metastatic colorectal cancer, with dose modifications of cabozantinib improving tolerability. Further study is warranted to identify biomarkers for patient populations most likely to benefit.
Article
Oncology
Alexandros Georgiou, Adam Stewart, Georgios Vlachogiannis, Lisa Pickard, Nicola Valeri, David Cunningham, Steven R. Whittaker, Udai Banerji
Summary: This study found that activation of the PI3K pathway is a potential mechanism of cetuximab resistance in KRAS/NRAS/BRAF(V600) wild-type CRC. The results suggest that the combination of PI3K pathway inhibitors with cetuximab can significantly reduce colony formation capacity in resistant cell lines.
Article
Oncology
Giovanni Randon, Giulia Maddalena, Marco Maria Germani, Chiara Carlotta Pircher, Paolo Manca, Francesca Bergamo, Mirella Giordano, Caterina Sposetti, Aldo Montagna, Guglielmo Vetere, Luca Zambelli, Cosimo Rasola, Alessandra Boccaccino, Filippo Pagani, Margherita Ambrosini, Marco Massafra, Gabriella Fontanini, Massimo Milione, Matteo Fassan, Chiara Cremolini, Sara Lonardi, Filippo Pietrantonio
Summary: This study identified rare genomic alterations beyond RAS and BRAFV600E mutations that drive primary resistance to anti-EGFR therapy in metastatic colorectal cancer, highlighting the need for further investigation to maximize the benefit of EGFR blockade strategies.
JCO PRECISION ONCOLOGY
(2022)
Article
Medicine, General & Internal
Rona Yaeger, Jared Weiss, Meredith S. Pelster, Alexander Spira, Minal Barve, Sai-Hong Ou, Ticiana A. Leal, Tanios S. Bekaii-Saab, Cloud P. Paweletz, Grace A. Heavey, James G. Christensen, Karen Velastegui, Thian Kheoh, Hirak Der-Torossian, Samuel J. Klempner
Summary: In this study, the researchers investigated the clinical efficacy of adagrasib in combination with cetuximab for heavily pretreated patients with metastatic colorectal cancer harboring mutant KRAS G12C. The results showed that the overall response rate was 19% in the adagrasib monotherapy group, with a median progression-free survival of 5.6 months, and 46% in the combination therapy group, with a median progression-free survival of 6.9 months. Both groups experienced reversible adverse events.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Chung-Ta Lee, Chien-An Chu, Yu-Ming Wang, Yi-Wen Wang, Yi-Lin Chen, Chung-Liang Ho, Yu-Min Yeh, Peng-Chan Lin, Bo-Wen Lin, Po-Chuan Chen, Shang-Hung Chen, Ren-Hao Chan, Chen Chang, Nan-Haw Chow
Summary: Sprouty2 (SPRY2) is a protein that inhibits the RAS/MAPK/ERK pathway and has potential for cancer research. This study investigated the effect of SPRY2 in colorectal cancer (CRC) and its relationship with KRAS mutation. The results showed that SPRY2 knockdown in Caco-2 cells with wild-type KRAS gene upregulated phosphorylated ERK levels and increased cell proliferation but inhibited invasion. However, SPRY2 knockdown did not significantly affect cell function in SW480 cells with activating KRAS mutation or Caco-2 cells transfected with KRAS-mutant plasmid. Additionally, the study found that high SPRY2 expression was associated with poorer cancer-specific survival in both KRAS-WT and KRAS-mutant CRC patients.
MOLECULAR CARCINOGENESIS
(2023)
Review
Oncology
Raymond C. Wadlow, David P. Ryan
Article
Oncology
Nils D. Arvold, David P. Ryan, Andrzej Niemierko, Lawrence S. Blaszkowsky, Eunice L. Kwak, Jennifer Y. Wo, Jill N. Allen, Jeffrey W. Clark, Raymond C. Wadlow, Andrew X. Zhu, Carlos Fernandez-del Castillo, Theodore S. Hong
Article
Oncology
Jennifer A. Chan, Lawrence Blaszkowsky, Keith Stuart, Andrew X. Zhu, Jill Allen, Raymond Wadlow, David P. Ryan, Jeffrey Meyerhardt, Marielle Gonzalez, Eileen Regan, Hui Zheng, Matthew H. Kulke
Article
Oncology
Andrea L. Russo, Darrell R. Borger, Jackie Szymonifka, David P. Ryan, Jennifer Y. Wo, Lawrence S. Blaszkowsky, Eunice L. Kwak, Jill N. Allen, Raymond C. Wadlow, Andrew X. Zhu, Janet E. Murphy, Jason E. Faris, Dora Dias-Santagata, Kevin M. Haigis, Leif W. Ellisen, Anthony J. Iafrate, Theodore S. Hong
Article
Biochemistry & Molecular Biology
Claudia Scholl, Stefan Froehling, Ian F. Dunn, Anna C. Schinzel, David A. Barbie, So Young Kim, Serena J. Silver, Pablo Tamayo, Raymond C. Wadlow, Sridhar Ramaswamy, Konstanze Doehner, Lars Bullinger, Peter Sandy, Jesse S. Boehm, David E. Root, Tyler Jacks, William C. Hahn, D. Gary Gilliland
Article
Oncology
Nils D. Arvold, Christopher G. Willett, Carlos Fernandez-del Castillo, David P. Ryan, Cristina R. Ferrone, Jeffrey W. Clark, Lawrence S. Blaszkowsky, Vikram Deshpande, Andrzej Niemierko, Jill N. Allen, Eunice L. Kwak, Raymond C. Wadlow, Andrew X. Zhu, Andrew L. Warshaw, Theodore S. Hong
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2012)
Article
Oncology
Theodore S. Hong, David P. Ryan, Darrell R. Borger, Lawrence S. Blaszkowsky, Beow Y. Yeap, Marek Ancukiewicz, Vikram Deshpande, Shweta Shinagare, Jennifer Y. Wo, Yves Boucher, Raymond C. Wadlow, Eunice L. Kwak, Jill N. Allen, Jeffrey W. Clark, Andrew X. Zhu, Cristina R. Ferrone, Harvey J. Mamon, Judith Adams, Barbara Winrich, Tarin Grillo, Rakesh K. Jain, Thomas F. DeLaney, Carlos Fernandez-del Castillo, Dan G. Duda
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2014)
Article
Oncology
Lipika Goyal, Raymond C. Wadlow, Lawrence S. Blaszkowsky, Brian M. Wolpin, Thomas A. Abrams, Nadine Jackson McCleary, Susan Sheehan, Eamala Sundaram, Michael D. Karol, John Chen, Andrew X. Zhu
INVESTIGATIONAL NEW DRUGS
(2015)
Article
Multidisciplinary Sciences
David A. Barbie, Pablo Tamayo, Jesse S. Boehm, So Young Kim, Susan E. Moody, Ian F. Dunn, Anna C. Schinzel, Peter Sandy, Etienne Meylan, Claudia Scholl, Stefan Froehling, Edmond M. Chan, Martin L. Sos, Kathrin Michel, Craig Mermel, Serena J. Silver, Barbara A. Weir, Jan H. Reiling, Qing Sheng, Piyush B. Gupta, Raymond C. Wadlow, Hanh Le, Sebastian Hoersch, Ben S. Wittner, Sridhar Ramaswamy, David M. Livingston, David M. Sabatini, Matthew Meyerson, Roman K. Thomas, Eric S. Lander, Jill P. Mesirov, David E. Root, D. Gary Gilliland, Tyler Jacks, William C. Hahn
Article
Multidisciplinary Sciences
Raymond C. Wadlow, Ben S. Wittner, S. Aidan Finley, Henry Bergquist, Rabi Upadhyay, Stephen Finn, Massimo Loda, Umar Mahmood, Sridhar Ramaswamy
Article
Oncology
Marc T. Roth, Dana Backlund Cardin, Erkut Hasan Borazanci, Margaux Steinbach, Vincent J. Picozzi, Alexander Rosemury, Raymond Couric Wadlow, Robert A. Newman, Jordan Berlin
Article
Oncology
Andrea Bullock, Keith Stuart, Susanna Jacobus, Thomas Abrams, Raymond Wadlow, Michael Goldstein, Rebecca Miksad
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2017)
Article
Oncology
Marwan Al-Hajeili, Anthony E. Shields, Jimmy J. Hwang, Raymond C. Wadlow, John L. Marshall
Review
Medicine, Research & Experimental
R Wadlow, S Ramaswamy
CURRENT MOLECULAR MEDICINE
(2005)
